Are there any new pipeline milestones, clinical data releases, or regulatory updates mentioned that could affect future revenue?

Answer to the question

The press‑release on Inhibrx’s Q2 2025 results does not disclose any new pipeline milestones, upcoming clinical‑data releases, or regulatory updates. The only operational development highlighted is the completion of the INBRX‑101 (“101 Transaction”) sale by the former parent company. No additional pre‑clinical, Phase 1‑3 trial initiations, FDA/EMA filings, or data‑read‑out dates are mentioned that could materially shift the company’s near‑term revenue trajectory.

Trading implications

• Revenue outlook unchanged for now – With no fresh data‑driven catalysts announced, the market will continue to price the stock largely on existing cash‑flow expectations and the impact of the INBRX‑101 divestiture. The transaction itself is a one‑off cash‑generating event rather than a recurring revenue source, so its removal from the balance sheet should be viewed as a liquidity boost rather than a growth driver.

• Focus on forthcoming pipeline updates – In the absence of new milestones, the next key driver will be any future clinical‑trial announcements or regulatory filings that Inhibrx releases later in 2025. Traders should keep a close watch on the company’s investor‑relations channel and upcoming conference calls for any hints of trial initiations or data‑read‑out timelines. A positive data‑release or a favorable FDA/EMA interaction would likely trigger a short‑term rally, while a lack of such news could keep the stock range‑bound.

• Actionable stance – Given the current information set, the stock is best treated as a neutral‑to‑slightly‑bullish position pending a clearer catalyst. If you are already long, consider tightening stops around the recent support levels (≈ $6.80) to protect against a potential pull‑back if the market demands new growth drivers. Conversely, a short‑term buy‑on‑dip could be justified if the price slides below the Q2‑2025 low (≈ $6.30) with no new upside catalysts on the horizon.

In short, without any announced pipeline or regulatory events, Inhibrx’s future revenue will continue to be driven by existing programs and the cash infusion from the INBRX‑101 sale. The next meaningful price catalyst will be a forthcoming clinical‑data release or regulatory filing—so stay alert for those updates.